Findings of Research Misconduct, 18638-18639 [2015-07897]

Download as PDF 18638 Federal Register / Vol. 80, No. 66 / Tuesday, April 7, 2015 / Notices RECORD SOURCE CATEGORIES: Records are obtained directly from the subject individuals, or from the following sources: educational institutions; internship and/or residency training programs; employers; NHSCapproved service sites; critical shortage facilities; schools of nursing; lending institutions and loan servicing agencies; health professional associations; National Practitioner Data Bank; System for Awards Management (formerly Excluded Parties List System); HHS Office of Inspector General Web site listing of individuals excluded from Medicare, Medicaid, and all other federal health care programs; HHS database of Health Professional Shortage Areas; HHS grantees and contractors/ subcontractors; consumer reporting agencies/credit bureaus; other federal agencies, including but not limited to the Department of the Treasury, IRS, and the U.S. Postal Service; state health professions licensing boards and/or the Federation of State Medical Boards or a similar non-government entity; and third parties who provide references or other information concerning the subject individual. SYSTEM EXEMPTED FROM CERTAIN PROVISIONS OF THE ACT: None. [FR Doc. 2015–07899 Filed 4–6–15; 8:45 am] BILLING CODE CODE 4160–15–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Findings of Research Misconduct Office of the Secretary, HHS. Notice. AGENCY: ACTION: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Teresita L. Briones, Ph.D., Wayne State University: Based on the report of an inquiry conducted by Wayne State University (WSU) and additional analysis conducted by ORI in its oversight review, ORI found that Dr. Teresita L. Briones, former Associate Professor, College of Nursing, WSU, engaged in research misconduct in research supported by National Institute of Nursing Research (NINR), National Institutes of Health (NIH), grants P30 NR009014, R01 NR005260, and R01 NR007666. ORI found that Respondent intentionally, knowingly, and recklessly engaged in research misconduct by falsifying and/or fabricating data that mstockstill on DSK4VPTVN1PROD with NOTICES SUMMARY: VerDate Sep<11>2014 17:46 Apr 06, 2015 Jkt 235001 were included in five (5) publications and three (3) grant applications submitted to NINR, NIH: Behavioural Brain Research 279:112–22, 2015 Feb 15 (hereafter referred to as ‘‘BBR 2015’’) • Journal of Neuroinflammation 11:13, 2014 Jan 22 (hereafter referred to as ‘‘JNI 2014’’) • Journal of Neurotrauma 26(4):613–25, 2009 Apr (hereafter referred to as ‘‘JNT 2009’’) • Journal of Neurotrauma 28(12):2485– 92, 2011 Dec (hereafter referred to as ‘‘JNT 2011’’) • Neuroscience 262:143–55, 2014 Mar 14 (hereafter referred to as ‘‘NS 2014’’) • R01 NR011167–01 • R01 NR011167–01A1 • R01 NR 011167–01A2 ORI found that Respondent falsified and/or fabricated data by falsely reporting the results of Western blot experiments that examined neuroinflammation, amyloidogenesis, and/or cognitive impairment in a rat model of cerebral ischemia. Specifically, Respondent duplicated, reused, and falsely relabeled Western blot gel images and claimed they represented different experiments in: • BBR 2015, Figures 2E and 5D • JNI 2014, Figures 2A and 2C • JNT 2009, Figures 2B and 5 • JNT 2011, Figure 2 • NS 2014, Figure 4 • R01 NR011167–01, Figures 5 and 6 • R01 NR011167–01A1, Figures 4A and 4B • R01 NR011167–01A2, Figures 4A and 4B As a result of this Agreement, Respondent will request that the following publications be retracted: BBR 2015, JNI 2014, JNT 2009, JNT 2011, and NS 2014. Dr. Briones has entered into a Voluntary Exclusion Agreement (Agreement) and has voluntarily agreed for a period of three (3) years, beginning on March 12, 2015: (1) to exclude herself from any contracting or subcontracting with any agency of the United States Government and from eligibility for or involvement in nonprocurement programs of the United States Government referred to as ‘‘covered transactions’’ pursuant to HHS’ Implementation (2 CFR part 376 et seq) of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively the ‘‘Debarment Regulations’’); (2) to exclude herself voluntarily from serving in any advisory capacity to the U.S. Public Health Service (PHS) including, but not limited to, service on any PHS advisory committee, board, PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 and/or peer review committee, or as a consultant; and (3) to request that the following publications be retracted: BBR 2015, JNI 2014, JNT 2009, JNT 2011, and NS 2014. FOR FURTHER INFORMATION CONTACT: Acting Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453– 8200. Donald Wright, Acting Director, Office of Research Integrity. [FR Doc. 2015–07896 Filed 4–6–15; 8:45 am] BILLING CODE CODE 4150–31–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Findings of Research Misconduct Office of the Secretary, HHS. Notice. AGENCY: ACTION: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Ryousuke Fujita, Ph.D., Columbia University: Based on the report of an investigation conducted by Columbia University (CU) and additional analysis conducted by ORI in its oversight review, ORI found that Dr. Ryousuke Fujita, former Postdoctoral Scientist, Taub Institute for the Aging Brain, Departments of Pathology and Cell Biology and Neurology, CU Medical Center, engaged in research misconduct in research supported by National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), grant R01 NS064433 and National Institute of Aging (NIA), NIH, grant R01 AG042317. ORI found that Respondent engaged in research misconduct by falsifying and fabricating data for specific protein expressions in human-induced neuronal (hiN) cells derived skin fibroblasts of Alzheimer’s disease patients and unaffected individuals in seventy-four (74) panels included in figures in the following two (2) publications and one (1) unpublished manuscript: • Cell 146:359–371, 2011 (hereafter referred to as ‘‘Cell 2011’’). • Nature 500:45–53, 2013 (hereafter referred to as ‘‘Nature 2013’’). • ‘‘Human induced neuron models of APOE4-associated Alzheimer’s disease display altered APP endocytosis and processing.’’ Unpublished manuscript. ORI found that Respondent engaged in research misconduct by knowingly and intentionally fabricating and falsifying research in seventy-four (74) SUMMARY: E:\FR\FM\07APN1.SGM 07APN1 Federal Register / Vol. 80, No. 66 / Tuesday, April 7, 2015 / Notices mstockstill on DSK4VPTVN1PROD with NOTICES panels included in figures in Cell 2011, Nature 2013, and the unpublished manuscript. Respondent inflated sample numbers and data, fabricated numbers for data sets, manipulated enzymelinked immunosorbent assay (ELISA) analysis, mislabelled immunoflourescent confocal images, and manipulated and reused Western blot images. Specifically, the Respondent • Fabricated numbers for the data presented as a bar graph in nine (9) panels in Figures S6#, S6H, and S6J in Cell 2011, Figures 3B and S12 in Nature 2013, and Figures 2F, 4B, 4D, and 4F in the unpublished manuscript Falsely inflated the sample size of quantitative data presented as bar graphs in fifty-three (53) panels in Figures 6B, 7I, and S6J in Cell 2011, Figures 3G, 3H, 4C, S10, S11b–h, S12d–f, S13a, S13c, S14b–c, S15b–i, and S16a–f in Nature 2013, and Figures 4b, 4d, 4f, 4i, 6c–d, S1n, S1o, S2a–b, and S4c–k in the unpublished manuscript Falsely manipulated ELISA analysis to achieve desired results presented as bar graphs in nine (9) figure-panels in Figure 6B in Cell 2011 and Figures 2D, 2E, 3G, 3H, and S10a–d in Nature 2013 Falsely inflated the numerical values of the data in Figure 7I in Cell 2011 by a factor of 10 to improve results and appear consistent with data presented in supplementary information published with the paper Falsely reversed the labeling of immunoflourescent confocal images in Figures 7M and 7N in Cell 2011 and Figure S13A in Nature 2013 to obtain the desired results Flipped and resized the Western blot image for APP panel from Figure 12b and falsely reused it to represent APP results under completely different experimental conditions in Figure 12c in Nature 2013 Dr. Fujita has entered into a Voluntary Exclusion Agreement (Agreement) and has voluntarily agreed for a period of three (3) years, beginning on March 18, 2015: (1) to exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility for or involvement in nonprocurement programs of the United States Government referred to as ‘‘covered transactions’’ pursuant to HHS’ Implementation (2 CFR part 376 et seq) of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively the ‘‘Debarment Regulations’’); and VerDate Sep<11>2014 17:46 Apr 06, 2015 Jkt 235001 (2) to exclude himself voluntarily from serving in any advisory capacity to the U.S. Public Health Service (PHS) including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. FOR FURTHER INFORMATION CONTACT: Acting Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453– 8200. Donald Wright, Acting Director, Office of Research Integrity. [FR Doc. 2015–07897 Filed 4–6–15; 8:45 am] BILLING CODE CODE 4150–31–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Meeting of the National Advisory Committee on Children and Disasters Office of the Secretary, Department of Health and Human Services. ACTION: Notice. AGENCY: As stipulated by the Federal Advisory Committee Act, the Department of Health and Human Services (HHS) is hereby giving notice that the National Advisory Committee on Children and Disasters (NACCD) will be holding a meeting via teleconference. The meeting is open to the public. DATES: The April 30, 2015, NACCD meeting is scheduled from 1:00 p.m. to 2:00 p.m. EST. The agenda is subject to change as priorities dictate. Please check the NACCD Web site, located at WWW.PHE.GOV/NACCD for the most up-to-date information on the meeting. ADDRESSES: To attend the meeting via teleconference, call toll-free: 1–888– 324–4311, international dial-in: 1–517– 308–9181. The pass-code is: 4818002. Please call 15 minutes prior to the beginning of the conference call to facilitate attendance. Pre-registration is required for public attendance. Individuals who wish to attend the meeting should submit an inquiry via the NACCD Contact Form located at www.phe.gov/NACCDComments. FOR FURTHER INFORMATION CONTACT: Please submit an inquiry via the NACCD Contact Form located at www.phe.gov/ NACCDComments. SUMMARY: Pursuant to the Federal Advisory Committee Act (FACA) of 1972 (5 U.S.C., Appendix, as amended), and section 2811A of the Public Health Service (PHS) Act (42 U.S.C. 300hh–10a), as added by section 103 of the Pandemic and All Hazards SUPPLEMENTARY INFORMATION: PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 18639 Preparedness Reauthorization Act of 2013 (Pub. L. 113–5), the HHS Secretary, in consultation with the Secretary of the U.S. Department of Homeland Security, established the National Advisory Committee on Children and Disasters (NACCD). The purpose of the NACCD is to provide advice and consultation to the HHS Secretary with respect to the medical and public health needs of children in relation to disasters. The Office of the Assistant Secretary for Preparedness and Response (ASPR) provides management and administrative oversight to support the activities of the NACCD. Background: This public meeting will be dedicated to the members voting to approve the report of findings of the NACCD Surge Capacity Work Group. Availability of Materials: The meeting agenda and materials will be posted on the NACCD Web site at: www.phe.gov/ naccd prior to the meeting. Procedures for Providing Public Input: All written comments must be received prior to April 29, 2015. Please submit comments via the NACCD Contact Form located at www.phe.gov/ NACCDComments. Individuals who plan to participate by phone and need special assistance should submit a request via the NACCD Contact Form located at www.phe.gov/ NACCDComments. Dated: March 18, 2015. Nicole Lurie, Assistant Secretary for Preparedness and Response. [FR Doc. 2015–07874 Filed 4–6–15; 8:45 am] BILLING CODE CODE P DEPARTMENT OF HEALTH AND HUMAN SERVICES Indian Health Service Reimbursement Rates for Calendar Year 2015 Indian Health Service, HHS. Notice. AGENCY: ACTION: Notice is given that the Director of the Indian Health Service (IHS), under the authority of sections 321(a) and 322(b) of the Public Health Service Act (42 U.S.C. 248 and 249(b)), Public Law 83–568 (42 U.S.C. 2001(a)), and the Indian Health Care Improvement Act (25 U.S.C. 1601 et seq.), has approved the following rates for inpatient and outpatient medical care provided by IHS facilities for Calendar Year 2015 for Medicare and Medicaid beneficiaries, and beneficiaries of other Federal programs, SUMMARY: E:\FR\FM\07APN1.SGM 07APN1

Agencies

[Federal Register Volume 80, Number 66 (Tuesday, April 7, 2015)]
[Notices]
[Pages 18638-18639]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-07897]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has taken final action in the following case:
    Ryousuke Fujita, Ph.D., Columbia University: Based on the report of 
an investigation conducted by Columbia University (CU) and additional 
analysis conducted by ORI in its oversight review, ORI found that Dr. 
Ryousuke Fujita, former Postdoctoral Scientist, Taub Institute for the 
Aging Brain, Departments of Pathology and Cell Biology and Neurology, 
CU Medical Center, engaged in research misconduct in research supported 
by National Institute of Neurological Disorders and Stroke (NINDS), 
National Institutes of Health (NIH), grant R01 NS064433 and National 
Institute of Aging (NIA), NIH, grant R01 AG042317.
    ORI found that Respondent engaged in research misconduct by 
falsifying and fabricating data for specific protein expressions in 
human-induced neuronal (hiN) cells derived skin fibroblasts of 
Alzheimer's disease patients and unaffected individuals in seventy-four 
(74) panels included in figures in the following two (2) publications 
and one (1) unpublished manuscript:
     Cell 146:359-371, 2011 (hereafter referred to as ``Cell 
2011'').
     Nature 500:45-53, 2013 (hereafter referred to as ``Nature 
2013'').
     ``Human induced neuron models of APOE4-associated 
Alzheimer's disease display altered APP endocytosis and processing.'' 
Unpublished manuscript.
    ORI found that Respondent engaged in research misconduct by 
knowingly and intentionally fabricating and falsifying research in 
seventy-four (74)

[[Page 18639]]

panels included in figures in Cell 2011, Nature 2013, and the 
unpublished manuscript. Respondent inflated sample numbers and data, 
fabricated numbers for data sets, manipulated enzyme-linked 
immunosorbent assay (ELISA) analysis, mislabelled immunoflourescent 
confocal images, and manipulated and reused Western blot images.

Specifically, the Respondent

 Fabricated numbers for the data presented as a bar graph in 
nine (9) panels in Figures S6#, S6H, and S6J in Cell 2011, Figures 3B 
and S12 in Nature 2013, and Figures 2F, 4B, 4D, and 4F in the 
unpublished manuscript
Falsely inflated the sample size of quantitative data presented as bar 
graphs in fifty-three (53) panels in Figures 6B, 7I, and S6J in Cell 
2011, Figures 3G, 3H, 4C, S10, S11b-h, S12d-f, S13a, S13c, S14b-c, 
S15b-i, and S16a-f in Nature 2013, and Figures 4b, 4d, 4f, 4i, 6c-d, 
S1n, S1o, S2a-b, and S4c-k in the unpublished manuscript
Falsely manipulated ELISA analysis to achieve desired results presented 
as bar graphs in nine (9) figure-panels in Figure 6B in Cell 2011 and 
Figures 2D, 2E, 3G, 3H, and S10a-d in Nature 2013
Falsely inflated the numerical values of the data in Figure 7I in Cell 
2011 by a factor of 10 to improve results and appear consistent with 
data presented in supplementary information published with the paper
Falsely reversed the labeling of immunoflourescent confocal images in 
Figures 7M and 7N in Cell 2011 and Figure S13A in Nature 2013 to obtain 
the desired results
Flipped and resized the Western blot image for APP panel from Figure 
12b and falsely reused it to represent APP results under completely 
different experimental conditions in Figure 12c in Nature 2013

    Dr. Fujita has entered into a Voluntary Exclusion Agreement 
(Agreement) and has voluntarily agreed for a period of three (3) years, 
beginning on March 18, 2015:
    (1) to exclude himself from any contracting or subcontracting with 
any agency of the United States Government and from eligibility for or 
involvement in nonprocurement programs of the United States Government 
referred to as ``covered transactions'' pursuant to HHS' Implementation 
(2 CFR part 376 et seq) of OMB Guidelines to Agencies on Governmentwide 
Debarment and Suspension, 2 CFR part 180 (collectively the ``Debarment 
Regulations''); and
    (2) to exclude himself voluntarily from serving in any advisory 
capacity to the U.S. Public Health Service (PHS) including, but not 
limited to, service on any PHS advisory committee, board, and/or peer 
review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT: Acting Director, Office of Research 
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 
453-8200.

Donald Wright,
Acting Director, Office of Research Integrity.
[FR Doc. 2015-07897 Filed 4-6-15; 8:45 am]
BILLING CODE CODE 4150-31-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.